Roisin O’Brien

Dr. Roisin O’Brien is an Analyst at Outcome Capital. Trained formally as a scientist, Dr. O’Brien leverages her scientific and research expertise in support of the Firm’s clients throughout all life science verticals.

Prior to her investment banking career, Dr. O’Brien focused her doctoral studies on characterizing the molecular mechanisms of CRISPR-Cas genome editing technologies through complementary structural and biophysical techniques. She published multiple peer-reviewed, first-author manuscripts in such journals including Nature Communications and Molecular Cell. Alongside her PhD studies, Dr. O’Brien consulted for the University of Texas at Austin Office of Technology and Commercialization life sciences division. Roisin worked with licensing specialists to effectively market technologies developed at UT Austin and facilitate licensing agreements with biotech/pharma corporations. In addition, Roisin advised numerous pre-revenue and post-revenue venture start-ups on successful go-to-market strategies through Jon Brumley Texas Ventures.

Dr. O’Brien holds a B.A. degree in Biochemistry from the University of San Diego and earned her PhD in Biochemistry from the University of Texas at Austin.